TIM-3 blockade enhances ex vivo stimulated allogeneic NK cell therapy for relapsed murine neuroblastoma after hematopoietic cell transplant
Allo-HCT can be a platform for treating NBL using combination ex vivo stimulated allogeneic NK cell therapy with TIM-3 blockade to enhance the GVT effect without inducing GVHD.
Authors
- Chloe King
- Nicholas R Mohrdieck
- Katharine E. Tippins
- Sean Rinella
- Monica Moonkyung Cho (ORCID: https://orcid.org/0000-0002-6708-9578)
- Evan L. Dray (ORCID: https://orcid.org/0000-0002-9293-7583)
- Anastasia A Griggs
- Tyce Kearl
- Longzhen Song
- Christian M. Capitini (ORCID: https://orcid.org/0000-0002-2276-6731)
- Aicha Quamine (ORCID: https://orcid.org/0000-0002-9049-7078)
- Nicholas J Hess (ORCID: https://orcid.org/0000-0001-5720-9305)
- Paul D. Bates
- Bryon D. Johnson (ORCID: https://orcid.org/0000-0001-7416-3396)
- Lei Shi
- Jillian M Kline
Institutions
- University of Wisconsin–Madison (US)
- Medical College of Wisconsin (US)
- University of Wisconsin Carbone Cancer Center (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/jitc-2024-010239
- Citations
- 1
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- National Science Foundation
- U.S. Department of Health and Human Services
- University of Wisconsin-Madison
- University of Wisconsin Carbone Cancer Center
- Midwest Athletes Against Childhood Cancer
- National Institutes of Health
- National Cancer Institute
- National Institute of General Medical Sciences